Some researchers and users hypothesize that combining them could produce additive effects: tirzepatide reducing caloric intake and improving metabolic health from the top down, while AOD 9604 enhances lipolysis at the tissue level from the bottom up
That distinction affects consent, safety monitoring, and accountability
This manifests as: Persistent fatigue and weakness Breathlessness, particularly on exertion Palpitations or rapid heartbeat Pale or jaundiced (yellowish) skin Glossitis (sore, red tongue) Neurological and psychiatric symptoms can be particularly concerning and may become irreversible if deficiency remains untreated for extended periods
Using CY 2024 claims data, CPT codes 0652T, 0653T, and 0654T had geometric mean costs of $1,897.72, $1,107.54, $1,064.23, ( respectively, in the CY 2026 OPPS/ASC proposed rule
For GLP-1 comparison, read semaglutide vs tirzepatide